Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome. Issue 11 (1st June 2017)

• Record Type: Journal Article
• Authors: Sattigeri, Jitendra A.; Sethi, Sachin; Davis, Joseph A.; Ahmed, Shahadat; Rayasam, Geeta V.; Jadhav, Balasaheb G.; Chilla, Satya M.; Datta, Dhrubajyoti; Gadhave, A.; Tulasi, Vamshi K.; Jain, Tarun; Voleti, Sreedhara; Benjamin, Biju; Udupa, Sunitha; Jain, Garima; Singh, Yogender; Srinivas, Kona; Bansal, Vinay S.; Ray, Abhijit; Bhatnagar, Pradip K.; Cliffe, Ian A.
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 27:Issue 11(2017)
• Page Start: 2313
• Page End: 2318
• Publication Date: 2017-06-01
• Subjects: DPP4-ACE dual inhibitor; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2017.04.036
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.